Publications by authors named "Pilar Cazorla"

Claim this Profile
R
Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies.
Pierre N Tariot, Marie-Emmanuelle Riviere, Stephen Salloway, Jeffrey M Burns, Jón G Snaedal, Pilar Cazorla

Alzheimers Dement· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
Marie-Emmanuelle Riviere, Jessica B Langbaum, R Scott Turner, Juha O Rinne, Yihan Sui, Pilar Cazorla

Alzheimers Dement· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Enriqueta Felip, Filippo G de Braud, Michela Maur, Herbert H Loong, Alice Tsang Shaw, Pilar Cazorla

J Thorac Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
David E Kemp, Jun Zhao, Pilar Cazorla, Ronald P Landbloom, Mary Mackle

J Clin Psychiatry· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.
Steven G Potkin, Phillip Phiri, Armin Szegedi, Jun Zhao, Larry Alphs, Pilar Cazorla

Schizophr Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder.
Keming Gao, Mary Mackle, Pilar Cazorla, Jun Zhao, Armin Szegedi

Neuropsychiatr Dis Treat· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis.
Pilar Cazorla, Jun Zhao, Mary Mackle, Armin Szegedi

Neuropsychiatr Dis Treat· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder.
Lenard A Adler, René A Kroon, Mark Stein, Mohammed Shahid, Frank I Tarazi, Pilar Cazorla

Biol Psychiatry· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Armin Szegedi, Pierre Verweij, Wilbert van Duijnhoven, Mary Mackle, Pilar Cazorla

J Clin Psychiatry· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia.
Pilar Cazorla, Mary Mackle, Jun Zhao, Xianwei Ha, Armin Szegedi

Neuropsychiatr Dis Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Robert W Buchanan, John Panagides, Jun Zhao, Phillip Phiri, Wil den Hollander, Pilar Cazorla

J Clin Psychopharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Training for assessment of negative symptoms of schizophrenia across languages and cultures: comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor.
David G Daniel, Larry Alphs, Pilar Cazorla, John J Bartko, John Panagides

Clin Schizophr Relat Psychoses· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia.
Larry Alphs, Robert Morlock, Cheryl Coon, Pilar Cazorla, Armin Szegedi

Int J Methods Psychiatr Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis